Myeloma Investment Fund - aVenture Asset Manager Research
Location
Brookline, MA, US
Founded
2019
The Myeloma Investment Fund focuses on early-stage biotech companies developing novel treatment strategies for multiple myeloma, an incurable and challenging disease. As a self-sustaining venture fund, it typically invests in Series A rounds, supporting companies that take on significant scientific and financial risks in their pursuit of innovative therapies.
The fund's portfolio includes notable companies such as Fortis Therapeutics, Indapta Therapeutics, and Triumvira Immunologics, which have collectively raised over $135 million. Through its investments, the Myeloma Investment Fund aims to provide reliable funding and world-class expertise to accelerate the development of new treatment options for multiple myeloma patients.
Myeloma Investment Fund - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies3
Current Portfolio Count3
Top Investment Stages
Series A3 (100.0%)
Stage Mix
Series A 100%
Concentration shown as share of disclosed investments by stage.
